Clinical Trial: Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.

U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07421856) titled 'Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.' on Dec. 17, 2025.

Brief Summary: To Evaluate Safety and Efficacy of S103 for Treating Relapsed or Refractory Multiple Myeloma

Study Start Date: Feb. 01

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma in Relapse Multiple Myeloma Refractory

Intervention: BIOLOGICAL: Autologous BCMA-targeting CAR T cells

Administration method: intravenous infusion;Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Hebei Senlang Biotechnolo...